• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫内膜基质细胞中尿激酶型纤溶酶原激活剂(UPA)的降解既需要UPA受体,也需要低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体。

Degradation of urokinase plasminogen activator (UPA) in endometrial stromal cells requires both the UPA receptor and the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor.

作者信息

Casslén B, Gustavsson B, Angelin B, Gåfvels M

机构信息

Department of Obstetrics and Gynecology, Lund University Hospital, Sweden.

出版信息

Mol Hum Reprod. 1998 Jun;4(6):585-93. doi: 10.1093/molehr/4.6.585.

DOI:10.1093/molehr/4.6.585
PMID:9665342
Abstract

Primary cultures of human endometrial stromal cells expressed a single class of specific high-affinity binding sites for urokinase plasminogen activator (UPA) with a dissociation constant KD 1.0 nmol/l and saturation at 2.0 nmol/l. Similar binding data and number of free binding sites, about 200 fmol/mg protein, were found for UPA in complex with its inhibitor plasminogen activator inhibitor-1 (PAI-1). These binding data agree with those reported for the specific cell surface receptor for UPA, and stromal cell expression of UPA receptor mRNA was identified in Northern blots. Cell surface-bound UPA was degraded at 37 degrees C. Degradation of complexed UPA was more efficient than that of free UPA. Degradation of free UPA did not require prior binding to endogenous PAI-1. Degradation of both free and complexed UPA was reduced by 70% by colchicine, chloroquine and methylamine, indicating that degradation involved both internalization and lysosomal enzymes. Furthermore, degradation was independently inhibited by about 70% with anti-UPA receptor antibodies and receptor-associated protein, indicating that the UPA receptor as well as one or more receptors of the low-density lipoprotein (LDL) receptor supergene family were involved in the degradation process. Receptor-associated protein ligand blotting demonstrated a major band co-migrating with the LDL receptor-related protein or glycoprotein 330/megalin, and a minor band co-migrating with the very low-density lipoprotein receptor. Immunoblotting positively demonstrated expression of LDL receptor-related protein, but not glycoprotein 330.

摘要

人子宫内膜基质细胞的原代培养物表达了一类单一的、对尿激酶型纤溶酶原激活剂(UPA)具有特异性高亲和力的结合位点,解离常数KD为1.0 nmol/l,在2.0 nmol/l时达到饱和。对于与抑制剂纤溶酶原激活剂抑制剂-1(PAI-1)结合的UPA,也发现了类似的结合数据和游离结合位点数量,约为200 fmol/mg蛋白质。这些结合数据与报道的UPA特异性细胞表面受体的数据一致,并且在Northern印迹中鉴定出了UPA受体mRNA的基质细胞表达。细胞表面结合的UPA在37℃下被降解。复合UPA的降解比游离UPA更有效。游离UPA的降解不需要事先与内源性PAI-1结合。秋水仙碱、氯喹和甲胺可使游离和复合UPA的降解减少70%,表明降解涉及内化和溶酶体酶。此外,抗UPA受体抗体和受体相关蛋白可使降解独立抑制约70%,表明UPA受体以及低密度脂蛋白(LDL)受体超基因家族的一个或多个受体参与了降解过程。受体相关蛋白配体印迹显示一条主要条带与LDL受体相关蛋白或糖蛋白330/巨膜蛋白共迁移,一条次要条带与极低密度脂蛋白受体共迁移。免疫印迹阳性证明了LDL受体相关蛋白的表达,但未证明糖蛋白330的表达。

相似文献

1
Degradation of urokinase plasminogen activator (UPA) in endometrial stromal cells requires both the UPA receptor and the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor.子宫内膜基质细胞中尿激酶型纤溶酶原激活剂(UPA)的降解既需要UPA受体,也需要低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体。
Mol Hum Reprod. 1998 Jun;4(6):585-93. doi: 10.1093/molehr/4.6.585.
2
Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.参与尿激酶-1型抑制剂复合物和尿激酶原与内吞性α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白结合的区域。尿激酶受体保护尿激酶原不与内吞性受体结合的证据。
J Biol Chem. 1994 Oct 14;269(41):25668-76.
3
Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.尿激酶型纤溶酶原激活物-纤溶酶原激活物抑制剂-1复合物与内吞作用受体α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白及极低密度脂蛋白受体的结合涉及抑制剂中的碱性残基。
Biochem J. 1998 Jan 1;329 ( Pt 1)(Pt 1):55-63. doi: 10.1042/bj3290055.
4
Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.纯化的α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白结合尿激酶-纤溶酶原激活物抑制剂1型复合物。α2-巨球蛋白受体介导尿激酶受体结合复合物细胞内降解的证据。
J Biol Chem. 1992 Jul 25;267(21):14543-6.
5
gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.II型肺泡上皮细胞上的gp330介导内吞作用,导致尿激酶原、纤溶酶原激活物抑制剂-1以及尿激酶-纤溶酶原激活物抑制剂-1复合物降解。
J Cell Sci. 1995 Jun;108 ( Pt 6):2361-8. doi: 10.1242/jcs.108.6.2361.
6
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.尿激酶受体通过α-2巨球蛋白受体/低密度脂蛋白受体相关蛋白(Lrp)依赖性内化作用。
J Cell Biol. 1995 Dec;131(6 Pt 1):1609-22. doi: 10.1083/jcb.131.6.1609.
7
Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.孕酮通过增加尿激酶型纤溶酶原激活物(u-PA)抑制剂及u-PA受体的表面表达,刺激子宫内膜基质细胞中u-PA的降解。
J Clin Endocrinol Metab. 1995 Sep;80(9):2776-84. doi: 10.1210/jcem.80.9.7673423.
8
Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.月经周期中子宫内膜组织中尿激酶型纤溶酶原激活剂(uPA)、其受体(uPAR)及其抑制剂(PAI-1)mRNA和蛋白的差异定位与表达。
Mol Hum Reprod. 2004 Sep;10(9):655-63. doi: 10.1093/molehr/gah081. Epub 2004 Jul 8.
9
Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.纤溶酶原激活物抑制剂1衍生肽对单链尿激酶结合、内化及降解的调节作用
J Biol Chem. 1997 Oct 24;272(43):27053-7. doi: 10.1074/jbc.272.43.27053.
10
Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.通过定点诱变确定尿激酶型纤溶酶原激活剂-纤溶酶原激活剂抑制剂-1复合物与低密度脂蛋白受体家族内吞作用受体的结合区域。
FEBS J. 2006 Nov;273(22):5143-59. doi: 10.1111/j.1742-4658.2006.05511.x. Epub 2006 Oct 17.

引用本文的文献

1
EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2.通过单链抗体片段M6-1B9胞内抗体降低EMMPRIN会影响α3β1整合素和MCT1的功能,并导致结肠癌细胞系Caco-2的进展性表型受到抑制。
Cancer Gene Ther. 2014 Jun;21(6):246-55. doi: 10.1038/cgt.2014.24. Epub 2014 Jun 13.
2
Immunohistochemical localization of low density lipoprotein (LDL) receptor-related protein-1 (LRP1) in the endometrium of cyclic and pregnant pigs.免疫组化定位低密度脂蛋白(LDL)受体相关蛋白-1(LRP1)在周期性和妊娠猪子宫内膜中的表达。
J Mol Histol. 2013 Jun;44(3):285-90. doi: 10.1007/s10735-012-9470-7. Epub 2012 Dec 9.